A 28-Day Oral Toxicity Study in Wistar Rats for a Highly Bioavailable Curcumin Preparation, CAVACURMIN®
Nutraceuticals · 22.12.2025 · 6 (1) · 2
DOI: 10.3390/nutraceuticals6010002 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nutraceuticals, online erschienen am 22.12.2025. Verfasst von Heiko Zipp und 4 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wacker Chemie AG.
Abstract (Originalsprache)
Curcumin is widely used for its antioxidant and anti-inflammatory properties, but its poor oral bioavailability has driven the development of advanced formulations such as CAVACURMIN®, a γ-cyclodextrin-based curcumin complex with enhanced absorption. Given recent regulatory scrutiny of high-bioavailability curcumin products, we evaluated the subacute oral safety of CAVACURMIN® in Wistar rats. Animals received 2000 mg/kg/day (low dose) or 3500 mg/kg/day (high dose) for 28 days, with controls receiving vehicle or γ-cyclodextrin alone. No mortality or systemic toxicity occurred, except for one incidental death unrelated to treatment. Transient post-dosing signs (salivation, bedding displacement) were attributed to local sensory or irritant effects. Clinical chemistry showed modest, non-adverse variations—including decreased urea (up to −25% in males) and increased albumin (up to +9% in females)—that were not associated with pathological or clinical abnormalities. All other parameters, including body weight, food intake, haematology, organ weights (except for a small, non-adverse liver-weight increase in high-dose females), and gross pathology, were comparable to controls. These findings demonstrate that CAVACURMIN® was well tolerated at doses up to 3500 mg/kg/day and provide a basis for subsequent OECD 408-compliant 90-day toxicity studies.
Förderung
- Wacker Chemie AG
Zitieren
APA
Zipp, H., Kellert, M., Rivera, N. L., Schmid, S., & Münch, G. (2025). A 28-Day Oral Toxicity Study in Wistar Rats for a Highly Bioavailable Curcumin Preparation, CAVACURMIN®. Nutraceuticals, 6(1), 2. https://doi.org/10.3390/nutraceuticals6010002
Vancouver
Zipp H, Kellert M, Rivera NL, Schmid S, Münch G. A 28-Day Oral Toxicity Study in Wistar Rats for a Highly Bioavailable Curcumin Preparation, CAVACURMIN®. Nutraceuticals. 2025;6(1):2. doi:10.3390/nutraceuticals6010002
BibTeX
@article{Zipp2025,
author = {Zipp, Heiko and Kellert, Marco and Rivera, Natascha Lara and Schmid, Sandra and Münch, Gerald},
title = {A 28-Day Oral Toxicity Study in Wistar Rats for a Highly Bioavailable Curcumin Preparation, CAVACURMIN®},
journal = {Nutraceuticals},
year = {2025},
volume = {6},
number = {1},
pages = {2},
doi = {10.3390/nutraceuticals6010002}
}
EUVIMED